Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation

被引:27
|
作者
Nelson, Winnie W. [1 ]
Wang, Li [2 ]
Baser, Onur [3 ,4 ]
Damaraju, Chandrasekharrao V. [5 ]
Schein, Jeffrey R. [1 ]
机构
[1] Janssen Sci Affairs LLC, Hlth Econ & Outcomes Res HECOR, Raritan, NJ 08869 USA
[2] STATinMED Res, Plano, TX USA
[3] STATinMED Res, Ann Arbor, MI USA
[4] MEF Univ, Istanbul, Turkey
[5] Janssen Res & Dev LLC, Raritan, NJ USA
关键词
Atrial fibrillation; Clinical outcomes; International normalized ratio; USA; US veterans; Warfarin; RISK-FACTOR; ANTICOAGULATION CONTROL; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULANT; PREDICTING STROKE; INTENSITY; HOSPITALS; QUALITY;
D O I
10.1007/s11096-014-0038-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Although efficacious in stroke prevention in non-valvular atrial fibrillation, many warfarin patients are sub-optimally managed. Objective To evaluate the association of international normalized ratio control and clinical outcomes among new warfarin patients with non-valvular atrial fibrillation. Setting Adult non-valvular atrial fibrillation patients (a parts per thousand yen18 years) initiating warfarin treatment were selected from the US Veterans Health Administration dataset between 10/2007 and 9/2012. Method Valid international normalized ratio values were examined from the warfarin initiation date through the earlier of the first clinical outcome, end of warfarin exposure or death. Each patient contributed multiple in-range and out-of-range time periods. Main outcome measure The relative risk ratios of clinical outcomes associated with international normalized ratio control were estimated. Results 34,346 patients were included for analysis. During the warfarin exposure period, the incidence of events per 100 person-years was highest when patients had international normalized ratio < 2:13.66 for acute coronary syndrome; 10.30 for ischemic stroke; 2.93 for transient ischemic attack; 1.81 for systemic embolism; and 4.55 for major bleeding. Poisson regression confirmed that during periods with international normalized ratio < 2, patients were at increased risk of developing acute coronary syndrome (relative risk ratio: 7.9; 95 % confidence interval 6.9-9.1), ischemic stroke (relative risk ratio: 7.6; 95 % confidence interval 6.5-8.9), transient ischemic attack (relative risk ratio: 8.2; 95 % confidence interval 6.1-11.2), systemic embolism (relative risk ratio: 6.3; 95 % confidence interval 4.4-8.9) and major bleeding (relative risk ratio: 2.6; 95 % confidence interval 2.2-3.0). During time periods with international normalized ratio > 3, patients had significantly increased risk of major bleeding (relative risk ratio: 1.5; 95 % confidence interval 1.2-2.0). Conclusion In a Veterans Health Administration non-valvular atrial fibrillation population, exposure to out-of-range international normalized ratio values was associated with significantly increased risk of adverse clinical outcomes.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [21] Impact of stroke risk factors on warfarin prescription among patients with non-valvular atrial fibrillation
    Zhao, Yu-Hui
    Zhang, Ting
    Du, Xin
    Wen, Dan
    Shang, Mei-Sheng
    Ma, Chang-Sheng
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (08): : 16587 - 16595
  • [22] Management of Stable Anticoagulated Patients with Out-of-Range INR Values
    Selvig, Daniel
    Barnes, Geoffrey D.
    Kaatz, Scott
    Winfield, Julia
    Gu, Xiaokui
    Haymart, Brian
    Kline-Rogers, Eva
    Almany, Steve
    Kozlowski, Jay
    Hickman, Leaden
    Besley, Dennis
    Leyden, Thomas
    Froehlich, James B.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 : S155 - S155
  • [23] Predictors of out-of-range INR for patients with atrial fibrillation on oral anticoagulation: results from ACTIVE
    Flaker, G.
    Tait, P.
    Goldhaber, S.
    Anand, I.
    Granger, C.
    Yusuf, S.
    Connolly, S.
    Pfeffer, M.
    [J]. EUROPEAN HEART JOURNAL, 2006, 27 : 38 - 38
  • [24] Comparative Effectiveness of Dabigatran versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Alonso, Alvaro
    Chen, Lin Y.
    MacLehose, Richard F.
    Lutsey, Pamela L.
    [J]. CIRCULATION, 2013, 128 (22)
  • [25] Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
    Breithardt, Guenter
    Baumgartner, Helmut
    Berkowitz, Scott D.
    Hellkamp, Anne S.
    Piccini, Jonathan P.
    Lokhnygina, Yuliya
    Halperin, Jonathan L.
    Singer, Daniel E.
    Hankey, Graeme J.
    Hacke, Werner
    Becker, Richard C.
    Nessel, Christopher C.
    Mahaffey, Kenneth W.
    Califf, Robert M.
    Fox, Keith A. A.
    Patel, Manesh R.
    [J]. HEART, 2016, 102 (13) : 1036 - 1043
  • [26] INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation
    Chung, Jee Eun
    Choi, Yoo Ri
    Seong, Jong Mi
    La, Hyen O.
    Gwak, Hye Sun
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (06) : 1038 - 1046
  • [27] Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US
    Schoof, Nils
    Schnee, Janet
    Schneider, Gary
    Gawlik, Melissa
    Zint, Kristina
    Clemens, Andreas
    Bartels, Dorothee B.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (05) : 795 - 804
  • [28] Under-use of warfarin for patients with non-valvular atrial fibrillation in Japan
    Inoue, H
    [J]. INTERNAL MEDICINE, 2004, 43 (07) : 529 - 530
  • [29] Warfarin utilization and stroke risk in patients with chronic non-valvular atrial fibrillation
    Boccuzzi, SJ
    Stephenson, JJ
    Kreilick, CA
    Beaulieu, JF
    Hauch, O
    Kim, J
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 335A - 335A
  • [30] INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation
    Jee Eun Chung
    Yoo Ri Choi
    Jong Mi Seong
    Hyen O La
    Hye Sun Gwak
    [J]. International Journal of Clinical Pharmacy, 2015, 37 : 1038 - 1046